Abstract:Objective To explore and analyze the relationship between subunit tetrahydrofolate reductase(MTHFR), glutathione S-transferase P1(GSTP1) gene polymorphisms and the sensitivity and prognosis of FOLFOX4 adjuvant chemotherapy after surgery for stage Ⅲ colon cancer.Methods Eighty-four patients with stage Ⅲ colon cancer who received FOLFOX4 adjuvant chemotherapy after operation in First Hospital of Hebei Medical University from March 2017 to January 2019 was selected as the research objects. MTHFR-rs1801131 and GSTP1-rs1695 gene polymorphisms of patients were detected. The patients were followed up for 3 years after operation. The correlation between different gene polymorphisms of MTHFR and GSTP1 and postoperative FOLFOX4 adjuvant chemotherapy sensitivity and 3-year survival rate was analyzed. Results The distribution of MTHFR-rs1801131 genotypes was as follows: AA type accounted for 78.57%, AC type accounted for 11.90%, CC type accounted for 9.52%, GSTP1-rs1695 genotype AA type accounted for 51.19%, AG type accounted for 38.10%, GC type accounted for 10.71%. There was no significant difference in chemosensitivity between AA genotype and AC/CC genotype patients with MTHFR-rs1801131 genotype (21.21% vs 27.78%, P=0.783). The GSTP1-rs1695 patients of AG/GC genotype, was more sensitive to chemotherapy than that of AA genotype (46.34% vs 18.60%, P=0.007). The 3-year survival rate of MTHFR-rs1801131 genotype AC/CC was significantly lower than that of AA type, the difference was statistically significant (11.11% vs 84.85%, P<0.01).Conclusions GSTP1-rs1695 genotype is AG/GC type Ⅲ colon cancer with higher sensitivity to postoperative FOLFOX4 adjuvant chemotherapy, MTHFR-rs1801131 genotype AA can ensure better prognosis after postoperative FOLFOX4 adjuvant chemotherapy for stage Ⅲ colon cancer and survival rate.